#1 - Gilead Sciences (NASDAQ:GILD)
Gilead Sciences (NASDAQ:GILD) is in the headlines for its therapeutic antiviral treatment called remdesivir. Gilead stock is essentially flat for the year, but investors have been on quite the ride. In the six weeks from the onset of the extreme mitigation efforts to the end of April, GILD stock charged ahead by 22%. But it’s since given up most of those gains.
Part of the reason for this is that the race for a vaccine took center stage, and it pulled investor attention away from therapeutics. And also, remdesivir was not seen as being an all-in-one solution for Covid-19. But if there’s anything the President’s treatment is showing it’s that remdesivir may still have a role to play as one of several therapeutic solutions.
But investors should be attracted to Gilead for other reasons. The company has an established pipeline that is not dependent on treating the novel coronavirus. And it also pays a respectable dividend.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More - Current Price
- $65.54
- Consensus Rating
- Hold
- Ratings Breakdown
- 7 Buy Ratings, 11 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $83.69 (27.7% Upside)
